{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:35:53Z","timestamp":1740173753373,"version":"3.37.3"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Temozolomide (TMZ) is an oral, systemic chemotherapy used chiefly for treating high-grade glioma. Due to the rising costs of systemic chemotherapy, many jurisdictions have replaced brand name with generic formulations. The aim of this study was to determine whether or not there was difference in the incidence of grade 3 or 4 bone marrow toxicity and median overall survival in patients treated with brand name versus generic TMZ in the province of Alberta, Canada. The province suspended the use of generic TMZ based on preliminary data pointing to excess toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multicenter, retrospective study included data from patients with newly diagnosed high-grade glioma that received treatment with TMZ in Alberta. Multivariate logistic regression analysis was performed to determine the association between grade 3 or 4 toxicity to generic versus brand name TMZ exposure, ECOG score, and age. Kaplan\u2013Meier survival estimates and log-rank testing were used to determine differences in overall survival between the brand name and generic TMZ cohorts, as well as the cytopenic versus non-cytopenic patients. Furthermore, a screening analysis for grade 3 or 4 bone marrow toxicity was conducted on all de novo glioma patients treated with brand name TMZ after Alberta preemptively stopped generic TMZ.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Grade 3 or 4 neutropenia and thrombocytopenia were observed in 15% and 19% of patients treated with generic TMZ (n = 156) as compared to 3% and 5% of patients (n = 100) treated with brand name TMZ-treated patients; P= .003 and .001. A trend toward increased median overall survival in glioblastoma patients treated with generic TMZ (13.7 months) versus brand name (15.8 months, P = .178.) was also observed through meeting statistical significance. Based on these results, the province stopped the use of generic TMZ and reverted to the Merck TMZ. An initial review of all new glioma patients (n = 89) treated with Merck TMZ since the province stopped the generic drug demonstrated 3.4% and 10.1% grade 3 or 4 neutropenia, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The statistically significant difference in toxicity profile has prompted the province of Alberta to replace generic TMZ with brand name TMZ in high-grade glioma patients pending more detailed analysis. Our study provides evidence supporting the importance of conducting prospective studies on long-term safety for generic chemotherapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npad065","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T03:01:12Z","timestamp":1698375672000},"page":"171-177","source":"Crossref","is-referenced-by-count":0,"title":["Switch to generic formulation of temozolomide results in statistically significant increase in grade 3 and 4 bone marrow toxicity in glioma patients in the province of Alberta"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6225-7093","authenticated-orcid":false,"given":"Egiroh","family":"Omene","sequence":"first","affiliation":[{"name":"Cross Cancer Institute , Edmonton, Alberta , Canada"},{"name":"Department of Medicine, University Alberta , Edmonton, Alberta , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Abdel-Rahman","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute , Edmonton, Alberta , Canada"},{"name":"Department of Medicine, University Alberta , Edmonton, Alberta , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Batuyong","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre , Calgary, Alberta , Canada"},{"name":"Department of Medicine, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Patel","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute , Edmonton, Alberta , Canada"},{"name":"Department of Medicine, University Alberta , Edmonton, Alberta , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Coppens","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute , Edmonton, Alberta , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Easaw","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute , Edmonton, Alberta , Canada"},{"name":"Department of Medicine, University Alberta , Edmonton, Alberta , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin","family":"Young","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute , Edmonton, Alberta , Canada"},{"name":"Department of Medicine, University Alberta , Edmonton, Alberta , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"issue":"4","key":"2024031506391268700_CIT0001","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-009-1050-5","article-title":"Temozolomide in malignant gliomas: current use and future targets","volume":"64","author":"Villano","year":"2009","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1","key":"2024031506391268700_CIT0002","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12885-015-1545-x","article-title":"Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma","volume":"15","author":"Adeberg","year":"2015","journal-title":"BMC Cancer"},{"issue":"2","key":"2024031506391268700_CIT0003","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1008382516636","article-title":"Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse","volume":"12","author":"Brada","year":"2001","journal-title":"Ann Oncol"},{"issue":"4","key":"2024031506391268700_CIT0004","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.phrs.2007.08.003","article-title":"Triazene compounds: mechanism of action and related DNA repair systems","volume":"56","author":"Marchese","year":"2007","journal-title":"Pharmacol Res."},{"issue":"8","key":"2024031506391268700_CIT0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3390\/jcm10081685","article-title":"Ewing sarcoma\u2014diagnosis, treatment, clinical challenges and future perspectives","volume":"10","author":"Z\u00f6llner","year":"2021","journal-title":"J Clin Med"},{"volume-title":"Merck Temodal Product Monograph, Merck Canada Inc","year":"2022","key":"2024031506391268700_CIT0006"},{"issue":"9","key":"2024031506391268700_CIT0007","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.clineuro.2013.05.015","article-title":"Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit","volume":"115","author":"Gupta","year":"2013","journal-title":"Clin Neurol Neurosurg."},{"issue":"34","key":"2024031506391268700_CIT0008","first-page":"484","article-title":"Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma","volume":"4","author":"Maxime","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"issue":"7","key":"2024031506391268700_CIT0009","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3346\/jkms.2014.29.7.980","article-title":"Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea","volume":"29","author":"Bae","year":"2014","journal-title":"J Korean Med Sci."},{"issue":"11","key":"2024031506391268700_CIT0010","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(16)30384-9","article-title":"Generic oncology drugs: are they all safe","volume":"17","author":"Yang","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"2024031506391268700_CIT0011","first-page":"474","article-title":"Comparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy","volume":"54","author":"Takahiro","year":"2012","journal-title":"J Radiat Res."},{"issue":"3","key":"2024031506391268700_CIT0012","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/jcpt.12823","article-title":"Ifosfamide-induced encephalopathy: brand-name (HOLOXAN\u00ae) vs generic formulation (IFOSFAMIDE EG\u00ae)","volume":"44","author":"J\u00e9r\u00e9my","year":"2019","journal-title":"J Clin Pharmacy Therapeut"},{"issue":"26","key":"2024031506391268700_CIT0013","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.2018.78.3290","article-title":"Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology","volume":"36","author":"\u00d6zdemir","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"2024031506391268700_CIT0014","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/CAD.0b013e328356f5b0","article-title":"Temozolomide-related idiosyncratic and other uncommon toxicities","volume":"23","author":"Dixit","year":"2012","journal-title":"Anticancer Drugs."},{"volume-title":"GSK Lamictal Product Monograph, GlaxoSmithKline Inc","year":"2021","key":"2024031506391268700_CIT0015"},{"volume-title":"Auro Levitiracetam Product Monograph, Auro Pharma Inc","year":"2017","key":"2024031506391268700_CIT0016"},{"issue":"11","key":"2024031506391268700_CIT0017","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npad065\/53253891\/npad065.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/11\/2\/171\/56918307\/npad065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/11\/2\/171\/56918307\/npad065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T06:55:19Z","timestamp":1710485719000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/11\/2\/171\/7330808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,10,27]]},"published-print":{"date-parts":[[2024,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npad065","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"type":"print","value":"2054-2577"},{"type":"electronic","value":"2054-2585"}],"subject":[],"published-other":{"date-parts":[[2024,4,1]]},"published":{"date-parts":[[2023,10,27]]}}}